These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22245427)

  • 1. Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro... A possible explanation for their mechanism of action in treating multiple myeloma.
    Shannon E; Sandoval F; Greig N; Stagg P
    Int Immunopharmacol; 2012 Feb; 12(2):441-6. PubMed ID: 22245427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide inhibited the synthesis of IgM and IgG whereas Thalidomide+Dexamethasone and Dexamethasone alone acted as co-stimulants with pokeweed and enhanced their synthesis.
    Shannon EJ; Sandoval F
    Int Immunopharmacol; 2010 Apr; 10(4):487-92. PubMed ID: 20123041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
    Gay F; Hayman SR; Lacy MQ; Buadi F; Gertz MA; Kumar S; Dispenzieri A; Mikhael JR; Bergsagel PL; Dingli D; Reeder CB; Lust JA; Russell SJ; Roy V; Zeldenrust SR; Witzig TE; Fonseca R; Kyle RA; Greipp PR; Stewart AK; Rajkumar SV
    Blood; 2010 Feb; 115(7):1343-50. PubMed ID: 20008302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.
    Raja KR; Plasil M; Rihova L; Pelcova J; Adam Z; Hajek R
    Cytometry B Clin Cytom; 2014 Jul; 86(4):220-8. PubMed ID: 23922218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
    Gay F; Vincent Rajkumar S; Falco P; Kumar S; Dispenzieri A; Petrucci MT; Gertz MA; Boccadoro M; Keith Stewart A; Palumbo A
    Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
    Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE
    Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.
    Harada T; Ozaki S; Oda A; Fujii S; Nakamura S; Miki H; Kagawa K; Takeuchi K; Matsumoto T; Abe M
    Int J Hematol; 2013 Jun; 97(6):743-8. PubMed ID: 23609417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
    Lee SE; Lim JY; Ryu DB; Kim TW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim M; Min CK
    Cancer Immunol Immunother; 2016 Aug; 65(8):983-94. PubMed ID: 27342591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
    Zonder JA; Crowley J; Hussein MA; Bolejack V; Moore DF; Whittenberger BF; Abidi MH; Durie BG; Barlogie B
    Blood; 2010 Dec; 116(26):5838-41. PubMed ID: 20876454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.
    Chang DH; Liu N; Klimek V; Hassoun H; Mazumder A; Nimer SD; Jagannath S; Dhodapkar MV
    Blood; 2006 Jul; 108(2):618-21. PubMed ID: 16569772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.
    Touzeau C; Blin N; Clavert A; Roland V; Loirat M; Tessoulin B; Le Gouill S; Planche L; Pennetier M; Mahe B; Mohty M; Malard F; Peterlin P; Dubruille V; Moreau P
    Leuk Lymphoma; 2012 Jul; 53(7):1318-20. PubMed ID: 22211836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
    Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
    Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of IL-2 and IL-6 on the immunoglobulin synthesis of lymphocytes from CVID patients].
    Rump JA; Schlesier M; Wolf-Vorbeck G; Dräger R; Melchers I; Peter HH
    Immun Infekt; 1990 Jun; 18(3):93-5. PubMed ID: 2379934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.
    Shiao RT; McLeskey SB; Khera SY; Wolfson A; Freter CE
    Leuk Lymphoma; 1996 Apr; 21(3-4):293-303. PubMed ID: 8726410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
    Scott LJ; Lyseng-Williamson KA
    BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low frequency of CD3
    Lee SE; Lim JY; Ryu DB; Kim TW; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min CK
    Ann Hematol; 2018 Nov; 97(11):2163-2171. PubMed ID: 29938309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Quality of Life Is Associated with Combined Lenalidomide and Dexamethasone Treatment in Japanese Patients with Relapsed or Refractory Multiple Myeloma].
    Sato H; Nakamura Y; Oi N; Namba K; Taniguchi Y; Yahata H; Komori H; Kobayashi H
    Gan To Kagaku Ryoho; 2015 Dec; 42(13):2461-6. PubMed ID: 26809305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How lenalidomide is changing the treatment of patients with multiple myeloma.
    Dimopoulos MA; Terpos E; Niesvizky R
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for neutropenia with lenalidomide plus dexamethasone therapy for multiple myeloma.
    Mitani Y; Usami E; Kimura M; Nakao T; Okada K; Matsuoka T; Kokuryou T; Yoshimura T; Yamakawa M
    Pharmazie; 2016 Jun; 71(6):349-51. PubMed ID: 27455556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.